Your browser doesn't support javascript.
Effectiveness of mRNA Booster Vaccination Against Mild, Moderate, and Severe COVID-19 Caused by the Omicron Variant in a Large, Population-Based, Norwegian Cohort.
Laake, Ida; Skodvin, Siri N; Blix, Kristine; Caspersen, Ida Henriette; Gjessing, Håkon K; Juvet, Lene K; Magnus, Per; Mjaaland, Siri; Robertson, Anna H; Starrfelt, Jostein; Trogstad, Lill; Feiring, Berit.
  • Laake I; Department of Method Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway.
  • Skodvin SN; Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.
  • Blix K; Department of Method Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway.
  • Caspersen IH; Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.
  • Gjessing HK; Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.
  • Juvet LK; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
  • Magnus P; Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway.
  • Mjaaland S; Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.
  • Robertson AH; Department of Method Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway.
  • Starrfelt J; Department of Method Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway.
  • Trogstad L; Department of Infection Control and Preparedness, Norwegian Institute of Public Health, Oslo, Norway.
  • Feiring B; Department of Method Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway.
J Infect Dis ; 226(11): 1924-1933, 2022 Nov 28.
Article in English | MEDLINE | ID: covidwho-2077787
ABSTRACT

BACKGROUND:

Understanding how booster vaccination can prevent moderate and severe illness without hospitalization is crucial to evaluate the full advantage of mRNA boosters.

METHODS:

We followed 85 801 participants (aged 31-81 years) in 2 large population-based cohorts during the Omicron BA.1/2 wave. Information on home testing, PCR testing, and symptoms of coronavirus disease 2019 (COVID-19) was extracted from biweekly questionnaires covering the period 12 January 2022 to 7 April 2022. Vaccination status and data on previous SARS-CoV-2 infection were obtained from national registries. Cox regression was used to estimate the effectiveness of booster vaccination compared to receipt of 2-dose primary series >130 days previously.

RESULTS:

The effectiveness of booster vaccination increased with increasing severity of COVID-19 and decreased with time since booster vaccination. The effectiveness against severe COVID-19 was reduced from 80.9% shortly after booster vaccination to 63.4% in the period >90 days after vaccination. There was hardly any effect against mild COVID-19. The effectiveness tended to be lower among subjects aged ≥60 years than those aged <50 years.

CONCLUSIONS:

This is the first population-based study to evaluate booster effectiveness against self-reported mild, moderate, and severe COVID-19. Our findings contribute valuable information on duration of protection and thus timing of additional booster vaccinations.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Infect Dis Year: 2022 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Infect Dis Year: 2022 Document Type: Article Affiliation country: Infdis